231 related articles for article (PubMed ID: 34230113)
1. Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects.
Veeramachaneni R; Yu W; Newton JM; Kemnade JO; Skinner HD; Sikora AG; Sandulache VC
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230113
[TBL] [Abstract][Full Text] [Related]
2. Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer.
Li L; Wang L; Li J; Fan Z; Yang L; Zhang Z; Zhang C; Yue D; Qin G; Zhang T; Li F; Chen X; Ping Y; Wang D; Gao Q; He Q; Huang L; Li H; Huang J; Zhao X; Xue W; Sun Z; Lu J; Yu JJ; Zhao J; Zhang B; Zhang Y
Cancer Res; 2018 Apr; 78(7):1779-1791. PubMed ID: 29374065
[TBL] [Abstract][Full Text] [Related]
3. Molecular targets of metformin antitumor action.
Sośnicki S; Kapral M; Węglarz L
Pharmacol Rep; 2016 Oct; 68(5):918-25. PubMed ID: 27362768
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
5. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
[TBL] [Abstract][Full Text] [Related]
6. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
7. Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?
Chandel NS; Avizonis D; Reczek CR; Weinberg SE; Menz S; Neuhaus R; Christian S; Haegebarth A; Algire C; Pollak M
Cell Metab; 2016 Apr; 23(4):569-70. PubMed ID: 27076070
[No Abstract] [Full Text] [Related]
8. Anti-diabetic drug metformin: challenges and perspectives for cancer therapy.
Snima KS; Pillai P; Cherian AM; Nair SV; Lakshmanan VK
Curr Cancer Drug Targets; 2014; 14(8):727-36. PubMed ID: 25329671
[TBL] [Abstract][Full Text] [Related]
9. Metformin plays an antitumor role by downregulating inhibitory cells and immune checkpoint molecules while activating protective immune responses in breast cancer.
Jiang H; Suo H; Gao L; Liu Y; Chen B; Lu S; Jin F; Cao Y
Int Immunopharmacol; 2023 May; 118():110038. PubMed ID: 36996738
[TBL] [Abstract][Full Text] [Related]
10. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
Guppy A; Jamal-Hanjani M; Pickering L
Future Oncol; 2011 Jun; 7(6):727-36. PubMed ID: 21675836
[TBL] [Abstract][Full Text] [Related]
11. Metformin: A Promising Antidiabetic Medication for Cancer Treatment.
Mu W; Jiang Y; Liang G; Feng Y; Qu F
Curr Drug Targets; 2023; 24(1):41-54. PubMed ID: 36336804
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Study of Inhibitory Effects of Metformin and Atorvastatin in Combination on Prostate Cancer Cells in Vitro and in Vivo.
Wang ZS; Huang HR; Zhang LY; Kim S; He Y; Li DL; Farischon C; Zhang K; Zheng X; Du ZY; Goodin S
Biol Pharm Bull; 2017; 40(8):1247-1254. PubMed ID: 28769006
[TBL] [Abstract][Full Text] [Related]
13. New perspective for an old antidiabetic drug: metformin as anticancer agent.
Leone A; Di Gennaro E; Bruzzese F; Avallone A; Budillon A
Cancer Treat Res; 2014; 159():355-76. PubMed ID: 24114491
[TBL] [Abstract][Full Text] [Related]
14. Metformin and cancer.
Rizos CV; Elisaf MS
Eur J Pharmacol; 2013 Apr; 705(1-3):96-108. PubMed ID: 23499688
[TBL] [Abstract][Full Text] [Related]
15. Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patient-Derived Xenografts.
Mohamed Suhaimi NA; Phyo WM; Yap HY; Choy SHY; Wei X; Choudhury Y; Tan WJ; Tan LAPY; Foo RSY; Tan SHS; Tiang Z; Wong CF; Koh PK; Tan MH
Mol Cancer Ther; 2017 Sep; 16(9):2035-2044. PubMed ID: 28533437
[TBL] [Abstract][Full Text] [Related]
16. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra I; Le Marchand-Brustel Y; Tanti JF; Bost F
Mol Cancer Ther; 2010 May; 9(5):1092-9. PubMed ID: 20442309
[TBL] [Abstract][Full Text] [Related]
17. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
Bahrambeigi S; Shafiei-Irannejad V
Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
[TBL] [Abstract][Full Text] [Related]
18. High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model.
Peng M; Su Q; Zeng Q; Li L; Liu Z; Xue L; Cheng Y; Huang Y; Tao T; Lv H; Li X; Tao X; Guo P; Chen AF; Yang X
Oncotarget; 2016 Feb; 7(8):9102-17. PubMed ID: 26802022
[TBL] [Abstract][Full Text] [Related]
19. Metformin targets ovarian cancer stem cells in vitro and in vivo.
Shank JJ; Yang K; Ghannam J; Cabrera L; Johnston CJ; Reynolds RK; Buckanovich RJ
Gynecol Oncol; 2012 Nov; 127(2):390-7. PubMed ID: 22864111
[TBL] [Abstract][Full Text] [Related]
20. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
